Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196216 | 0.89 | MEN1 (0.46) | NAAAKDM4EGPR84L3MBTL1MGLL | |
| SCHEMBL13484394 | 0.88 | NPC1 (0.50) | NAAAKDM4EGPR84L3MBTL1MGLL | |
| SCHEMBL3195226 | 0.85 | PSEN1 (0.43) | NAAAKDM4EGPR84L3MBTL1 | |
| SCHEMBL3195666 | 0.77 | NAAA (0.54) | NAAAKDM4EGPR84L3MBTL1ALDH1A1 | |
| SCHEMBL13484579 | 0.74 | PPARA (0.41) | PPARAPPARGTSHRPLA2G4BALDH1A1 | |
| SCHEMBL11750707 | 0.74 | PLA2G2A (0.49) | TSHRPLA2G4BL3MBTL1 | |
| SCHEMBL11749459 | 0.74 | PLA2G2A (0.49) | TSHRPLA2G4BL3MBTL1 | |
| SCHEMBL11186709 | 0.73 | NAAA (0.40) | NAAAL3MBTL1ALDH1A1 | |
| SCHEMBL162575 | 0.71 | SMN1; SMN2 (0.53) | NAAATSHRKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL159508 | 0.71 | RAB9A (0.50) | NAAATSHRKDM4EL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | FAS SECURED CREDITORS HOLDCO, LLC | 2010-02-04 | — | — | US | disclosed |
| WO-2007014249-A2 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | JOHNS HOPKINS UNIVERSITY (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029752-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME | CYP3A7, DHCR7, CYP2A7 | NAAA 3955/4885PPARA 1135/4885PPARG 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.